Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Encephalomyelitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Encephalomyelitis - Pipeline Review, H1 2015', provides an overview of the Encephalomyelitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Encephalomyelitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Encephalomyelitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Encephalomyelitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Encephalomyelitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Encephalomyelitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Encephalomyelitis Overview 6 Therapeutics Development 7 Pipeline Products for Encephalomyelitis - Overview 7 Pipeline Products for Encephalomyelitis - Comparative Analysis 8 Encephalomyelitis - Therapeutics under Development by Companies 9 Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes 10 Encephalomyelitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Encephalomyelitis - Products under Development by Companies 13 Encephalomyelitis - Products under Investigation by Universities/Institutes 14 Encephalomyelitis - Companies Involved in Therapeutics Development 15 Effimune SAS 15 Endocyte, Inc. 16 Immune Technologies and Medicine 17 InteKrin Therapeutics, Inc. 18 Io Therapeutics, Inc. 19 Merck & Co., Inc. 20 Momenta Pharmaceuticals, Inc. 21 Encephalomyelitis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 28 Drug Profiles 30 Anatabine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 EC-1496 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 FR-104 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 INT-131 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 IRX-5183 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 PETIR-001 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 PSA-20 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 SCH-546738 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 thymulin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Encephalomyelitis - Recent Pipeline Updates 44 Encephalomyelitis - Dormant Projects 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables Number of Products under Development for Encephalomyelitis, H1 2015 7 Number of Products under Development for Encephalomyelitis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Encephalomyelitis - Pipeline by Effimune SAS, H1 2015 15 Encephalomyelitis - Pipeline by Endocyte, Inc., H1 2015 16 Encephalomyelitis - Pipeline by Immune Technologies and Medicine, H1 2015 17 Encephalomyelitis - Pipeline by InteKrin Therapeutics, Inc., H1 2015 18 Encephalomyelitis - Pipeline by Io Therapeutics, Inc., H1 2015 19 Encephalomyelitis - Pipeline by Merck & Co., Inc., H1 2015 20 Encephalomyelitis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Encephalomyelitis Therapeutics - Recent Pipeline Updates, H1 2015 44 Encephalomyelitis - Dormant Projects, H1 2015 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
